vTv Therapeutics (NASDAQ: VTVT) and Pacira Pharmaceuticals (NASDAQ:PCRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Volatility and Risk
vTv Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Pacira Pharmaceuticals has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.
This table compares vTv Therapeutics and Pacira Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for vTv Therapeutics and Pacira Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
vTv Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 1,090.48%. Pacira Pharmaceuticals has a consensus target price of $46.88, indicating a potential upside of 2.03%. Given vTv Therapeutics’ higher probable upside, research analysts clearly believe vTv Therapeutics is more favorable than Pacira Pharmaceuticals.
Valuation and Earnings
This table compares vTv Therapeutics and Pacira Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|vTv Therapeutics||$290,000.00||150.07||-$16.14 million||($1.67)||-0.75|
|Pacira Pharmaceuticals||$286.63 million||6.57||-$42.61 million||($0.58)||-79.22|
vTv Therapeutics has higher earnings, but lower revenue than Pacira Pharmaceuticals. Pacira Pharmaceuticals is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.7% of vTv Therapeutics shares are held by institutional investors. 2.0% of vTv Therapeutics shares are held by insiders. Comparatively, 5.9% of Pacira Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Pacira Pharmaceuticals beats vTv Therapeutics on 8 of the 14 factors compared between the two stocks.
vTv Therapeutics Company Profile
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.